Shelf Eligibility, PIPE Integration, and an Affiliate's Secondary Sale
Halcyon Therapeutics completed its IPO eight months ago. It has 80 million shares outstanding, a $1.4 billion market capitalization and a $900 million public float, and has filed all periodic reports on time. It wants to raise $250 million of primary equity and simultaneously place $100 million of common stock privately with a strategic corporate investor at a 6% discount to the public offering price. The strategic investor demands resale registration rights, with a registration statement filed within 30 days of closing and effective within 90 days. A director who beneficially owns 3.0 million shares wants to sell 1.5 million shares as part of the same capital raise. Average weekly trading volume is 600,000 shares.
1. Is Halcyon eligible to use Form S-3 for the $250 million primary offering? Walk through the requirements and give the alternatives and a sequencing plan.
Read the worked answer
Form S-3 primary eligibility requires, among other things, (i) at least 12 calendar months of Exchange Act reporting with timely filing of all reports and (ii) a public float of at least $75 million.
Halcyon has $900 million of float but only 8 months of reporting. It fails the 12-month test and cannot use S-3 for a primary offering today. It is also not a well-known seasoned issuer, so no automatic shelf.
Options:
- File on Form S-1. Three years of audited financials, five years of selected data, 30-45 days of SEC review. Request acceleration and run a customary marketing period.
- Wait four months to become S-3 eligible and do a shelf takedown - unattractive if the cash need is now.
- Private placement under Section 4(a)(2)/Rule 506(b) with registration rights - but resale registration also needs a usable form, so the S-1 timetable has to be priced into the negotiation.
Recommendation: S-1 now, convert to S-3 at the 12-month mark for subsequent takedowns.
2. Analyze integration risk between the $250 million registered offering and the $100 million PIPE, and recommend a sequencing.
Read the worked answer
Integration turns on whether the two are one plan of financing: same class of security, same time, same consideration, same purpose. The registered offering necessarily involves general solicitation; a Rule 506(b) PIPE does not permit it. Marketing the PIPE while the public deal is live can destroy the 506(b) exemption.
Sequencing options:
- Close the PIPE first as a completed 4(a)(2)/506(b) placement with no general solicitation and no publicity, then launch the follow-on. Cleanest and recommended.
- Use 506(c) with accredited-investor verification. Permits solicitation but adds cost and delay for a single large ticket.
- Register the PIPE shares on the same S-1 as a resale. Avoids integration but makes the strategic a selling stockholder and potentially a statutory underwriter, and pulls the company into Section 11 liability.
Also flag the registration-rights deadlines: because the company is not yet S-3 eligible, the resale registration must be on an S-1, so 30/90 days is aggressive and should be negotiated to 45/120 with a suspension right and capped liquidated damages.
3. Can the director sell all 1.5 million shares now? Work the Rule 144 limits and identify the conditions and the alternative path.
Read the worked answer
Do the math rather than relying on the 1% rule of thumb.
- 1% of outstanding: 1% x 80M = 800,000 shares
- Four-week ADTV: 4 x 600,000 = 2,400,000 shares
- Rule 144 permits the greater of the two, so the limit is 2,400,000 shares per three-month period.
The 1.5 million shares requested is inside the limit. The director can sell under Rule 144.
Conditions still apply because the director is an affiliate: current public information, manner-of-sale requirements, and a Form 144 filing. Section 16(a) reporting applies, and Section 16(b) short-swing profit recapture applies if there was a purchase within six months.
Alternative: sell the shares in the registered offering. Rule 144 volume limits then do not apply, but the director must be named as a selling stockholder, the deal must accommodate secondary shares, and the director may be deemed an underwriter, changing the liability and indemnity analysis. Given the 2.4M ADTV limit, no registration is necessary.